Finasteride is the first 5α‐reductase inhibitor that received clinical approval for the treatment
of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair …

PURPOSE: To develop an evidence-based guideline on the use of 5-α-reductase inhibitors
(5-ARIs) for prostate cancer chemoprevention. METHODS: The American Society of Clinical …

CONTEXT: The sensitivity and specificity profile of measuring levels of prostate-specific
antigen (PSA) to select men for prostate biopsy is not optimal. This has prompted the …

Purpose Using data from men in the finasteride group of the Prostate Cancer Prevention
Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk …

One in 10 men in the developed world will present with prostate cancer (CaP), and in an
ageing population developing strategies for its chemoprevention or treatment is of …

Current male hormonal contraceptive (MHC) regimens act at various levels within the
hypothalamic pituitary testicular axis, principally to induce the withdrawal of the pituitary …

Androgenetic alopecia produces a chronic, progressive, patterned hair loss in both men and
women. Androgen hormones and, in particular, dihydrotestosterone bind to androgen …

OBJECTIVE: The 5-alpha-reductase type 2 (5A2) enzyme catalyses the irreversible
conversion of testosterone to dihydrotestosterone, the most active androgen in the prostate …

Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-
related morbidity, long latency between premalignant lesions and clinically evident cancer …

Prostate cancer chemoprevention involves the use of natural and/or synthetic agents that
inhibit or reverse the development of precancerous lesions or delay progression of these …